← All trials
NCT05122494
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2021
- Primary completion
- Feb 29, 2024
- Completion date
- Jun 30, 2024
- First posted
- Nov 16, 2021
- Last posted
- Nov 16, 2021
- Enrollment
- 339
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Hemay Pharmaceutical PTY. LTD.Lead sponsor
- Chinese Academy of Medical SciencesOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.